# Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19

> **NCT04403880** · — · COMPLETED · sponsor: **HIV Vaccine Trials Network** · enrollment: 760 (actual)

## Conditions studied

- SARS-CoV-2
- COVID-19

## Interventions

- **OTHER:** Sample collection

## Key facts

- **NCT ID:** NCT04403880
- **Lead sponsor:** HIV Vaccine Trials Network
- **Sponsor class:** NETWORK
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-13
- **Primary completion:** 2022-04-21
- **Final completion:** 2022-04-21
- **Target enrollment:** 760 (ACTUAL)
- **Last updated:** 2026-01-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04403880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04403880, "Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04403880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*